From Multiomics to Clinical Intelligence: Volv Global at Frontiers Health 2026
Volv Global at Frontiers Health's panel on AI & biomarker science translating complex biological signals into cli...
Volv Global helps you focus resources where the evidence shows unmet need. This helps to accelerate product launch, maximise commercial potential, and extend the product lifecycle by expanding the market to undiagnosed and misdiagnosed patients.
Identify high-need populations to drive strategic focus. Improve cohort segmentation using real-world data for optimal patient triage.
Streamline sales by mapping where likely-responding populations sit.
Expand beyond diagnosed individuals to include undiagnosed or misdiagnosed patients by understanding how large the undiagnosed and misdiagnosed population is beyond today's diagnosed count.
Match evolving market needs with deep disease understanding and competitive insights. Develop more impactful awareness and commercialisation strategies.
Commercial excellence in the face of complexity
Identifying high-need populations based on diverse and incomplete datasets.
Challenges in capturing the full care pathway, including missed or delayed diagnoses, delayed treatment, and the progression of untreated conditions.
Aligning disease understanding with market needs and competitive and evolving treatment paradigms.
Combining clinical, economic, and patient-reported data to drive strategy.
Supporting Commercial Excellence
Growing the real-world evidence on a disease, and a clearer view of how many people it affects.
Studying the early biomarker patterns that precede a condition, sometimes years before conventional signs appear.
Modelling how disease progresses across diagnosed populations, using real-world evidence.
Sizing the diagnosed population not yet on treatment, and showing where the gap to care opens.
Leading AI/ML methodology to support Commercial Excellence
For commercial teams, our machine learning methodology’s targeted engagement tools and comprehensive patient stratification capabilities offer a clearer picture of unmet needs across healthcare markets.
By recognising hidden patient clusters and forecasting disease trajectories, organisations can tailor outreach and education strategies that resonate with specific patient segments.
With its continuous learning from new data, our methodology ensures commercial strategies remain agile—empowering teams to refine their approach, highlight early detection benefits, and drive more precise and impactful market engagement.
Shaping the future today
Volv Global at Frontiers Health's panel on AI & biomarker science translating complex biological signals into cli...
Volv Global CEO Christopher Rudolf will speak at the DREAMS Neuromuscular Disease AI Webinar
Volv Global at the 25th Annual NEALS Meeting, presenting new research on early identification of ALS using advanced M...
Presenting new research on whether a machine learning model can flag which patients with CAP are most likely to progr...
The next useful thing AI does in solid tumour care is about timing, not detection. The patient must reach the right t...
Results for the model flagging early ARDS risk in pneumonia will be presented at ERS Congress 2026.
Volv Global at ERS Congress 2026, presenting new research in collaboration with CSL Behring: Can We Catch ARDS Before...
Volv Global applied machine learning to 24M UK primary care records, surfacing ~1,200 undiagnosed GEP-NET patients, 5...
GEP-NETs are among the most diagnostically elusive tumours in oncology. This case study shows how machine learning ap...
ASCO 2026 produced landmark oncology data. The question no one asked from the podium: can clinical infrastructure get...
Approximately 95% of rare diseases have no approved treatment. Drive For Change identifies three structural paradigms...
Machine learning applied to 3,549 confirmed Pompe disease patients – the largest machine learning study of the diseas...